Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

XenoPort

1999 FOUNDED
M&A STATUS
201-300 EMPLOYEES
Buyout/LBO LATEST DEAL TYPE
9 FINANCING ROUNDS
Description

Operator of a biopharmaceutical company intended to focus on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. The company's biopharmaceutical products include a potential treatment for patients with idiopathic Parkinson's disease and is currently commercializing HORIZANT (gabapentin enacarbil) extended-release tablets in the United States and developing its novel fumaric acid ester product candidate, XP23829, as a potential treatment for patients with moderate-to-severe chronic plaque-type psoriasis and potentially for relapsing forms of multiple sclerosis.

Ownership Status
Acquired/Merged
Financing Status
Private Equity-Backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Former Stock Listing
XNPT
Primary Office
  • 3410 Central Expressway
  • Santa Clara, CA 95051
  • United States

XenoPort Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore XenoPort‘s full profile, request access.

Request full access to PitchBook

XenoPort Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore XenoPort‘s full profile, request access.

Request full access to PitchBook

XenoPort Executive Team (12)

Name Title Board
Seat
Contact
Info
William Harris Chief Financial Officer & Senior Vice President, Finance
Francis Brennan Ph.D Associate Director, Medical Science
David Savello Ph.D Senior Vice President, Development Operations
Gregory Bates Ph.D Senior Vice President, Quality and Regulatory affairs
Paul Howe Vice President, Sales

6 Former Executives

You’re viewing 5 of 12 executives. Get the full list »